This article is more than 5 years old. Information may no longer be current.
Top ophthalmology news of the week
Click Here to Manage Email Alerts
Here are some of the top stories on Healio.com/OSN this week:
Notice of allowance for patent on corneal wound treatment issued to RegeneRx
RegeneRx Biopharmaceuticals has been issued a notice of allowance by the U.S. Patent and Trademark Office for a new patent for treating corneal wounds using thymosin beta 4 or related therapeutic peptides. Read more.
Training time adds minutes to patient encounters
The amount of time an attending ophthalmologist spends in a room with a patient is longer when a trainee is present, even when the trainee does not interact with the patient, according to a speaker at the American Association for Pediatric Ophthalmology and Strabismus meeting. Read more.
FDA accepts pSivida’s new drug application for Durasert
Two phase 3 studies of Durasert met their primary efficacy endpoints of reducing the recurrence of posterior segment uveitis in patients through 6 months of treatment. Read more.
Patients regain sight after treatment with retinal tissue from stem cells
Patients with sudden severe sight loss from wet AMD have regained reading vision after being implanted with an engineered patch of retinal pigment epithelium cells derived from stem cells. Read more.
Lucentis 0.3 mg prefilled syringe approved by FDA for all forms of diabetic retinopathy
Genentech announced the FDA approved the Lucentis 0.3 mg prefilled syringe to treat diabetic retinopathy with or without diabetic macular edema. Read more.